

April 29, 2025

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540, 890202

Scrip Code: SOLARA, SOLARAPP

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of a Wholly-owned Subsidiary

In furtherance to our earlier letter dated January 24, 2025 and February 7, 2025 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”), as amended, we wish to inform you that the Wholly-owned Subsidiary of the Company in the name of “Synthix Global Pharma Solutions Limited” is incorporated on April 29, 2025

The details required under Regulation 30 of the SEBI Listing Regulations, read with Schedule III thereto and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above incorporation of a Wholly-owned Subsidiary is given in Annexure enclosed herewith.

We request you to take the same on record and the same be treated as compliance under the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,
Yours faithfully,
For Solara Active Pharma Sciences Limited

S. Murali Krishna
Company Secretary & Compliance Officer

Encl.: As above

Annexure

Details under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	Details
1.	Name of the Target Company, details in brief such as size, turnover, etc.	<p>Synthix Global Pharma Solutions Limited</p> <p>Authorized Capital: Rs. 15,00,000/- (divided into 1,50,000 equity shares of Rs. 10 each) Paid up Capital: Rs.1,00,000/- (divided into 10,000 Equity shares of Rs. 10/- each)</p> <p>Size/Turnover: Yet to commence business</p>
2.	Whether the acquisition would fall within the related party transaction(s) and whether the promoter /promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	<p>The incorporated company being a wholly owned subsidiary is a related party of the Company.</p> <p>Save and except as mentioned above, the promoter/promoter group/ group companies are not interested.</p>
3.	Industry to which the entity being acquired belongs	Pharmaceuticals (Active Pharmaceutical Ingredients)
4.	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Wholly- owned Subsidiary is being incorporated in relation to proposed demerger of the CRAMS and Polymers Business into an Independent Entity.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6.	Indicative time period for completion of the acquisition	Not applicable
7.	Consideration - whether Cash consideration or share swap or any other form and details of the same	Subscription of shares in the incorporated company will be by way of cash consideration.
8.	Cost of acquisition and/or the price at which shares are acquired	<p>Synthix Global Pharma Solutions Limited is a wholly owned subsidiary of Solara Active Pharma Sciences Limited.</p> <p>Solara Active Pharma Sciences Limited along with its nominee shareholders has subscribed to 100% equity</p>

Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636

REGD. OFF: 201, Devavrata, Sector 17, Vashi Navi Mumbai - 400703. India/ Tel: 91-22-2789 2924 / 2789 3199 / Fax: 91-22-2789 2942

		shares of incorporated company amounting to Rs.1,00,000/-
9.	Percentage of shareholding/ control acquired and/ or number of shares acquired	100%
10.	Brief background about the entity acquired in terms of product/line of and business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Synthix Global Pharma Solutions Limited is incorporated on April 29, 2025 and is yet to commence operations.

For Solara Active Pharma Sciences Limited

S. Murali Krishna

Company Secretary & Compliance Officer